Vimarsana
Biggest News Aggregation in the World

Ujiie News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ujiie. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ujiie Today - Breaking & Trending Today

Japanese moon spaceship software confused by crater - Vimarsana News

Japanese moon spaceship software confused by crater

Apparently it did not expect them on the moon A post-mortem into the crash of the first private spaceship to land on the moon has found that the softw...

Health Canada accepts nirsevimab regulatory submission for infant RSV - Vimarsana News

Health Canada accepts nirsevimab regulatory submission for infant RSV

/CNW/ - Health Canada has accepted a New Drug Submission (NDS) for nirsevimab, the first investigational single-dose long-acting antibody designed for all...

Frontiers | Revisit the Sedimentary Stratigraphic Evolution and Environmental Changes on the Outer Shelf of the East China Sea Since MIS 5 - Vimarsana News

Frontiers | Revisit the Sedimentary Stratigraphic Evolution and Environmental Changes on the Outer Shelf of the East China Sea Since MIS 5

The East China Sea (ECS) is featured by the broad continental shelf, huge terrigenous sediment input and striking river-sea interaction during the Quaternary. Despite the numerous studies, mostly on the delta, coastal and inner shelf areas, the late Quaternary stratigraphy and sedimentary environment on the mid-outer ECS shelf were poorly documented. In particular, it is still controversial in issues such as the recognition of marine transgression deposits in the interglacial period and the occurrence and ages of deposits in the glacial period. This study presents new data of high-resolution s...

New nirsevimab data analyses reinforce efficacy against RSV - Vimarsana News

New nirsevimab data analyses reinforce efficacy against RSV

New nirsevimab data analyses reinforce efficacy against RSVA prespecified pooled analysis of Phase 3 and Phase 2b data demonstrated an efficacy of 79.5% against medically attended lower respiratory tract infections (LRTI), including hospitalizations, caused by respiratory syncytial virus (RSV)1Nirsevimab is the firs...

Nirsevimab significantly protected infants against RSV disease in Phase 3 trial - Vimarsana News

Nirsevimab significantly protected infants against RSV disease in Phase 3 trial

Nirsevimab significantly protected infants against RSV disease in Phase 3 trial - read this article along with other careers information, tips and advice on BioSpace